JP2023538449A5 - - Google Patents

Info

Publication number
JP2023538449A5
JP2023538449A5 JP2023513169A JP2023513169A JP2023538449A5 JP 2023538449 A5 JP2023538449 A5 JP 2023538449A5 JP 2023513169 A JP2023513169 A JP 2023513169A JP 2023513169 A JP2023513169 A JP 2023513169A JP 2023538449 A5 JP2023538449 A5 JP 2023538449A5
Authority
JP
Japan
Prior art keywords
mol
group
substituted
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538449A (ja
Filing date
Publication date
Priority claimed from GBGB2013221.3A external-priority patent/GB202013221D0/en
Priority claimed from GBGB2019097.1A external-priority patent/GB202019097D0/en
Priority claimed from GBGB2105404.4A external-priority patent/GB202105404D0/en
Application filed filed Critical
Priority claimed from PCT/GB2021/052199 external-priority patent/WO2022043678A1/en
Publication of JP2023538449A publication Critical patent/JP2023538449A/ja
Publication of JP2023538449A5 publication Critical patent/JP2023538449A5/ja
Pending legal-status Critical Current

Links

JP2023513169A 2020-08-24 2021-08-24 ウイルス阻害剤 Pending JP2023538449A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2013221.3 2020-08-24
GBGB2013221.3A GB202013221D0 (en) 2020-08-24 2020-08-24 Viral inhibitors
GB2019097.1 2020-12-03
GBGB2019097.1A GB202019097D0 (en) 2020-12-03 2020-12-03 Viral inhibitors
GBGB2105404.4A GB202105404D0 (en) 2021-04-15 2021-04-15 Viral inhibitors
GB2105404.4 2021-04-15
PCT/GB2021/052199 WO2022043678A1 (en) 2020-08-24 2021-08-24 Viral inhibitors

Publications (2)

Publication Number Publication Date
JP2023538449A JP2023538449A (ja) 2023-09-07
JP2023538449A5 true JP2023538449A5 (https=) 2024-08-14

Family

ID=77655566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513169A Pending JP2023538449A (ja) 2020-08-24 2021-08-24 ウイルス阻害剤

Country Status (8)

Country Link
US (1) US20230330132A1 (https=)
EP (1) EP4199937A1 (https=)
JP (1) JP2023538449A (https=)
CN (1) CN116367843A (https=)
AU (1) AU2021333748A1 (https=)
CA (1) CA3192515A1 (https=)
MX (1) MX2023002109A (https=)
WO (1) WO2022043678A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194032A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221941D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
CN100577179C (zh) * 2003-05-08 2010-01-06 天津帝士力投资控股集团有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
GB0615834D0 (en) 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
PL225045B1 (pl) * 2012-05-18 2017-02-28 Univ Jagiellonski Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
WO2020039463A1 (en) * 2018-08-23 2020-02-27 Haskoli Islands Chitosan derivatives and methods for preparing the same

Similar Documents

Publication Publication Date Title
EP0735859B1 (en) A pharmaceutical composition for the intranasal administration of hydroxocobalamin
JP2018188440A5 (https=)
HU197840B (en) Process for producing synergic pharmaceutical compositions comprising amantadin and selegilin
RU2001108569A (ru) Стабилизированная фармацевтическая композиция в лиофилизированной форме
RU2014139169A (ru) Парентеральные составы для введения макролидных антибиотиков
JP2022527556A5 (https=)
JP2002525329A5 (https=)
JP2022513089A5 (https=)
JP2024507788A5 (https=)
RU2009123536A (ru) Стабильные парентеральные составы, включающие ингибиторы pcb на основе бензодиазепина
JP2021534160A5 (https=)
JP2023538449A5 (https=)
RU2002128917A (ru) Полиаминные аналоги в качестве цитотоксических агентов
JP2023546565A5 (https=)
JP2025511227A5 (https=)
JP2025118775A5 (https=)
JP2006524227A5 (https=)
RU2002101622A (ru) Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом
RU99122032A (ru) Производные доластатина-15 в комбинации с таксанами
JP2008189677A (ja) 洗浄剤
JP2023520703A5 (https=)
KR910018341A (ko) 신규 α-만노시다제 및 푸코시다제 억제제
JP2025501169A5 (https=)
JP2016539100A5 (https=)
KR20070012522A (ko) 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방